NewcelX Ltd. reported a substantially wider operating loss for the first half of 2026 as increased research spending, Nasdaq-related public-company costs and business development expenses outweighed the absence of the unusually large financing charges that depressed the prior-year bottom line. The Switzerland-based clinical-stage biopharmaceutical company filed its interim consolidated financial statements and management discussion with the U.S. Securities and Exchange Commission on September 18, covering the six months ended June 30. The Form 6-K shows a company investing more heavily in its development platform while simultaneously managing a declining cash position and continued dependence on external financing.

The distinction between operating performance and the headline net result is important. NewcelX’s operating loss widened to $2.83 million from $1.36 million in the first half of 2025, an increase of approximately $1.47 million. At the same time, total net loss narrowed markedly to $2.90 million from $11.26 million. The apparent improvement at the net level was driven primarily by the disappearance of large non-cash financing expenses associated with convertible instruments in the year-earlier period rather than by revenue growth or operating profitability. The company generated no operating revenue in either six-month period.

Research and development expenses increased to $1.17 million from $576,000, a rise of $592,000, or more than 100%. Management attributed the increase principally to expanded R&D activity following the merger with NLS operations and continued advancement of NCEL-101, NewcelX’s lead development program for Type 1 diabetes. The company has identified NCEL-101 as its primary strategic focus and expects research spending to continue increasing as the program progresses toward clinical development.

NCEL-101 consists of enriched pancreatic islet cells designed to restore functional insulin production through an off-the-shelf cell-replacement approach. NewcelX said it is conducting IND-enabling work ahead of planned clinical development. The company disclosed that it completed a Type B pre-Investigational New Drug meeting with the U.S. Food and Drug Administration on July 1 concerning NCEL-101 in combination with Eledon Pharmaceuticals’ tegoprubart. According to NewcelX, the meeting provided feedback on the regulatory pathway, preclinical package and proposed Phase 1/2a clinical-trial design.

General and administrative expenses also rose sharply, reaching $1.66 million for the half year from $685,000 in the comparable 2025 period. NewcelX attributed the increase mainly to the inclusion of NLS-related expenses after the merger, including legal, accounting and other professional costs associated with operating as a Nasdaq-listed company. Business development spending also contributed to the increase. The higher G&A burden, combined with greater R&D spending, was the primary reason the operating loss more than doubled year over year.

The company recorded no merger-related expense in the first half of 2026, compared with $101,000 a year earlier, reflecting completion of the transaction through which Kadimastem merged into the group in October 2025. Following that transaction, the former NLS Pharmaceutics Ltd. adopted the NewcelX name, and Kadimastem’s operations became part of the consolidated company. The merger also changed the cost structure underlying the 2026 results, meaning year-over-year comparisons include the effects of a broader operating base and additional public-company expenses.

Below the operating line, the comparison moved in the opposite direction. Net financing expense was only $69,000 in the first half of 2026, down from $9.89 million a year earlier. The 2025 figure included approximately $9.92 million of financing expense connected with convertible instruments, largely arising from non-cash fair-value remeasurement of conversion features. Those convertible loans were subsequently converted in connection with the merger and are no longer outstanding, according to the filing. As a result, their accounting effect did not recur during the latest reporting period.

The elimination of that large prior-year charge produced a much narrower reported net loss despite deteriorating operating results. NewcelX posted a $2.90 million total loss for the first half, compared with $11.26 million a year earlier. MarketScreener, citing S&P Capital IQ data, also reported the $2.90 million net loss and basic and diluted loss per share of $0.96, compared with $3.68 in the prior-year period.

The loss available to common shareholders was larger than the reported total loss because of preferred-security adjustments. NewcelX recorded a $2.69 million deemed dividend and an additional $37,000 accrued dividend during the period, bringing net loss attributable to common shareholders to $5.63 million. Basic and diluted loss per common share was $0.96, based on a weighted-average 5.86 million common shares outstanding, compared with approximately 3.06 million shares in the first half of 2025. The prior-year loss available to common shareholders was $11.26 million.

Liquidity is a central feature of the filing. NewcelX ended June with $710,000 of cash and cash equivalents, down from $2.20 million at the beginning of 2026. Management said the decline reflected cash used in operations, including expenditures associated with NCEL-101. Total assets fell to approximately $9.70 million at June 30 from $11.45 million at year-end 2025, while total liabilities declined to $3.66 million from $4.20 million. Shareholders’ equity stood at approximately $6.0 million.

Operating cash usage increased considerably faster than the accounting loss comparison might initially suggest. Net cash used in operating activities was $2.87 million during the first half, versus $602,000 in the comparable 2025 period. Management attributed the increase to higher cash burn following the consolidation of NLS operations, public-company compliance costs, continued development of NCEL-101 and working-capital changes. With no cash generated from investing activities in either period, financing transactions remained the primary offset to operating outflows.

Financing activities supplied approximately $1.37 million of cash during the six months ended June 30, compared with $278,000 a year earlier. The increase primarily reflected proceeds from share and warrant issuances. NewcelX completed an April 2026 private placement with gross proceeds of $1.35 million, selling common shares and pre-funded warrants. The securities were accompanied by additional common warrants, whose potential cash exercise could provide further proceeds, although such warrant exercise is not assured.

After the reporting date, NewcelX raised additional capital. The company entered into securities purchase agreements on July 31 for a private placement of approximately $1.4 million and issued 347,134 common shares at $4.033 per share, together with warrants exercisable at $4.437 per share. The transaction closed on August 10. Full cash exercise of the associated warrants could generate roughly another $1.5 million in gross proceeds, according to management. Because that financing occurred after June 30, it is not included in the period-end cash balance of $710,000.

NewcelX also pointed to an existing committed equity facility under which it may sell up to $25 million of common shares to Alpha Capital Anstalt, subject to specified conditions and limitations. The arrangement allows NewcelX, under qualifying circumstances, to direct purchases at a price tied to 95% of the volume-weighted average market price during the applicable purchase date. For investors, the facility provides another potential source of liquidity, but future use could increase the company’s outstanding share count and create dilution depending on the amount and timing of equity issued.

Management’s liquidity assessment remained cautious even after considering available financing channels. NewcelX said it has incurred losses and generated negative operating cash flow since inception and does not expect meaningful product revenue in the near term. The company reported an accumulated deficit of approximately $90.5 million as of June 30. It expects to continue generating operating losses and negative cash flows as it funds clinical-development activities and pursues potential commercialization opportunities.

Based on its current operating plan, management said existing cash resources together with available financing sources may not be sufficient to meet operating and capital requirements for at least the next 12 months. The company therefore expects to require additional capital. Potential options cited in the filing include further equity or debt financing, strategic collaborations, partnerships, licensing arrangements and possible divestiture or monetization transactions involving selected assets.

The filing states that there is no assurance additional financing or strategic transactions will be available when required, in sufficient amounts or on favorable terms. Management therefore concluded that substantial doubt exists regarding the company’s ability to continue as a going concern. If sufficient funding cannot be secured, NewcelX said it could be forced to delay, reduce or eliminate research, development or commercialization programs. That disclosure places capital availability alongside clinical execution as a major variable for the company’s outlook.

The first-half numbers consequently present a mixed earnings picture. On a statutory net-loss basis, results improved substantially because an exceptional financing expense from 2025 did not repeat. On an operating basis, however, losses widened as the company increased investment in NCEL-101 and absorbed the post-merger cost structure. Meanwhile, cash usage accelerated and the balance-sheet cash position declined before the subsequent July financing.

For future reporting periods, the principal financial measures to watch will be the pace of R&D expenditure, operating cash burn, the company’s ability to raise additional capital and the extent to which financing transactions dilute existing shareholders. Clinical progress on NCEL-101 will remain directly connected to those financial requirements because advancing the program toward human trials is expected to require additional research, manufacturing, regulatory and clinical spending before NewcelX can generate product revenue.

NewcelX’s September 18 filing therefore underscores that the company remains in a development-stage financial profile: no operating revenue, widening core operating losses, significant reliance on external capital and a cash runway dependent on financing access. The sharp decline in reported net loss improves the year-over-year headline comparison, but it largely reflects the removal of prior-period financing-accounting effects. The more consequential earnings trend for investors is the increase in operating expenditure and cash consumption as NewcelX moves its lead diabetes program closer to clinical development.